Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/44024
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tam C.S. | - |
dc.contributor.author | Opat S. | - |
dc.contributor.author | Simpson D. | - |
dc.contributor.author | Cull G. | - |
dc.contributor.author | Munoz J. | - |
dc.contributor.author | Phillips T.J. | - |
dc.contributor.author | Kim W.S. | - |
dc.contributor.author | Rule S. | - |
dc.contributor.author | Atwal S.K. | - |
dc.contributor.author | Wei R. | - |
dc.contributor.author | Novotny W. | - |
dc.contributor.author | Huang J. | - |
dc.contributor.author | Wang M. | - |
dc.contributor.author | Trotman J. | - |
dc.date.accessioned | 2022-02-09T05:19:32Z | - |
dc.date.available | 2022-02-09T05:19:32Z | - |
dc.date.copyright | 2021 | - |
dc.date.issued | 2021-12-17 | en |
dc.identifier.citation | Blood Advances. 5(12) (pp 2577-2585), 2021. Date of Publication: 22 Jun 2021. | - |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/44024 | - |
dc.description.abstract | Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib was administered as 160 mg twice daily (n 5 14), 320 mg once daily (n 5 18), or #160 mg total dose (n 5 5). Herein, we report results for patients receiving a total daily dose of 320 mg (N 5 32). Median study follow-up was 18.8 months. Eighteen patients discontinued treatment, 10 because of progressive disease and 8 because of adverse events (AEs); 1 AE (peripheral edema) was considered to be related to zanubrutinib treatment. The most common AEs were diarrhea (43.8%), contusion (37.5%), constipation (31.3%), and upper respiratory tract infection (31.3%). Infection was the most commonly reported AE of interest (18.8% of patients experienced grade $3 infection). At least 1 AE of grade $3 was reported in 59.4% of patients; grade $3 AEs that were reported in .2 patients were anemia (12.5%), pneumonia (9.4%), and myalgia (9.4%). Overall response rate was 84%, with 25% achieving a complete response. Median duration of response was 18.5 months. Median progression-free survival (PFS) was 21.1 months. Zanubrutinib was well tolerated and demonstrated activity in patients with R/R MCL. The trial is registered at www.clinicaltrials.gov as #NCT02343120.Copyright © 2021 American Society of Hematology. All rights reserved. | - |
dc.publisher | American Society of Hematology | - |
dc.relation.ispartof | Blood Advances | - |
dc.subject.mesh | acute kidney failure | - |
dc.subject.mesh | allogeneic stem cell transplantation | - |
dc.subject.mesh | ANCA associated vasculitis | - |
dc.subject.mesh | anemia | - |
dc.subject.mesh | apoptosis | - |
dc.subject.mesh | atrial fibrillation | - |
dc.subject.mesh | bone marrow biopsy | - |
dc.subject.mesh | brain infarction | - |
dc.subject.mesh | cancer survival | - |
dc.subject.mesh | computer assisted tomography | - |
dc.subject.mesh | congestive heart failure | - |
dc.subject.mesh | constipation | - |
dc.subject.mesh | contusion | - |
dc.subject.mesh | diarrhea | - |
dc.subject.mesh | diffuse large B cell lymphoma | - |
dc.subject.mesh | drug dose reduction | - |
dc.subject.mesh | drug efficacy | - |
dc.subject.mesh | drug safety | - |
dc.subject.mesh | drug tolerability | - |
dc.subject.mesh | drug withdrawal | - |
dc.subject.mesh | epistaxis | - |
dc.subject.mesh | hematoma | - |
dc.subject.mesh | hematuria | - |
dc.subject.mesh | hypertension | - |
dc.subject.mesh | ischemic heart disease | - |
dc.subject.mesh | mantle cell lymphoma | - |
dc.subject.mesh | maximum tolerated dose | - |
dc.subject.mesh | myalgia | - |
dc.subject.mesh | myelodysplastic syndrome | - |
dc.subject.mesh | neutropenia | - |
dc.subject.mesh | peripheral edema | - |
dc.subject.mesh | pneumonia | - |
dc.subject.mesh | progression free survival | - |
dc.subject.mesh | recommended drug dose | - |
dc.subject.mesh | septic shock | - |
dc.subject.mesh | thrombocytopenia | - |
dc.subject.mesh | upper respiratory tract infection | - |
dc.subject.mesh | bendamustine | - |
dc.subject.mesh | bilirubin | - |
dc.subject.mesh | bortezomib | - |
dc.subject.mesh | rituximab | - |
dc.subject.mesh | voriconazole | - |
dc.subject.mesh | warfarin | - |
dc.subject.mesh | zanubrutinib | - |
dc.subject.mesh | zanubrutinib/ct | - |
dc.subject.mesh | computed tomography scanner | - |
dc.subject.mesh | PET-CT scanner | - |
dc.title | Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. | - |
dc.type | Article | - |
dc.identifier.affiliation | Haematology | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=https://dx.doi.org/10.1182/bloodadvances.2020004074 | - |
dc.publisher.place | United States | - |
dc.identifier.pubmedid | 34152395 [https://www.ncbi.nlm.nih.gov/pubmed/?term=34152395] | - |
dc.identifier.institution | (Opat) Monash Health, Clayton, VIC, Australia | en |
dc.identifier.institution | (Tam) Peter MacCallum Cancer Centre, Melbourne, VIC, Australia | en |
dc.identifier.institution | (Tam) St Vincent s Hospital, Fitzroy, VIC, Australia | en |
dc.identifier.institution | (Tam) Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia | en |
dc.identifier.institution | (Tam) Royal Melbourne Hospital, Parkville, VIC, Australia | en |
dc.identifier.institution | (Opat) Department of Haematology, Monash University, Clayton, VIC, Australia | en |
dc.identifier.institution | (Simpson) North Shore Hospital, Auckland, New Zealand | en |
dc.identifier.institution | (Simpson, Atwal, Wei, Novotny, Huang) BeiGene USA, Inc, San Mateo, CA, United States | en |
dc.identifier.institution | (Cull) Sir Charles Gairdner Hospital, Perth, WA, Australia | en |
dc.identifier.institution | (Cull) Pathology and Laboratory Medicine, University of Western Australia, Perth, WA, Australia | en |
dc.identifier.institution | (Munoz) Banner MD Anderson Cancer Center, Gilbert, AZ, United States | en |
dc.identifier.institution | (Phillips) Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States | en |
dc.identifier.institution | (Kim) Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea | en |
dc.identifier.institution | (Rule) Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom | en |
dc.identifier.institution | (Wang) University of Texas MD Anderson Cancer Center, Houston, TX, United States | en |
dc.identifier.institution | (Trotman) Concord Repatriation Hospital, University of Sydney, Sydney, NSW, Australia | en |
dc.subect.keywords | adult | - |
dc.subect.keywords | article | - |
dc.subect.keywords | clinical article | - |
dc.subect.keywords | clinical trial | - |
dc.subect.keywords | female | - |
dc.subect.keywords | follow up | - |
dc.subect.keywords | human | - |
dc.subect.keywords | male | - |
dc.identifier.affiliationext | (Tam) Peter MacCallum Cancer Centre, Melbourne, VIC, Australia | - |
dc.identifier.affiliationext | (Tam) St Vincent s Hospital, Fitzroy, VIC, Australia | - |
dc.identifier.affiliationext | (Tam) Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, VIC, Australia | - |
dc.identifier.affiliationext | (Tam) Royal Melbourne Hospital, Parkville, VIC, Australia | - |
dc.identifier.affiliationext | (Opat) Department of Haematology, Monash University, Clayton, VIC, Australia | - |
dc.identifier.affiliationext | (Simpson) North Shore Hospital, Auckland, New Zealand | - |
dc.identifier.affiliationext | (Simpson, Atwal, Wei, Novotny, Huang) BeiGene USA, Inc, San Mateo, CA, United States | - |
dc.identifier.affiliationext | (Cull) Sir Charles Gairdner Hospital, Perth, WA, Australia | - |
dc.identifier.affiliationext | (Cull) Pathology and Laboratory Medicine, University of Western Australia, Perth, WA, Australia | - |
dc.identifier.affiliationext | (Munoz) Banner MD Anderson Cancer Center, Gilbert, AZ, United States | - |
dc.identifier.affiliationext | (Phillips) Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, United States | - |
dc.identifier.affiliationext | (Kim) Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea | - |
dc.identifier.affiliationext | (Rule) Peninsula Medical School, University of Plymouth, Plymouth, United Kingdom | - |
dc.identifier.affiliationext | (Wang) University of Texas MD Anderson Cancer Center, Houston, TX, United States | - |
dc.identifier.affiliationext | (Trotman) Concord Repatriation Hospital, University of Sydney, Sydney, NSW, Australia | - |
dc.identifier.affiliationmh | (Opat) Monash Health, Clayton, VIC, Australia | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
crisitem.author.dept | Haematology | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.